About Event
Welcome to the 3rd TGF-β for Immuno-Oncology Drug Development
Exclusively Dedicated to Exploring the Role of TGF-β in Cancer Therapeutics
TGF-β is the unclaimed supergiant for IO, waiting for the efficacy and toxicity balancing act to be overcome. This target holds vast, exciting, therapeutic potential for drug developers – but with the complexity of this target, the field can learn from the recent clinical failures and go back to the basic science to overcome the pressing hurdles.
The 3rd TGF-β for Immuno-Oncology Drug Development Summit will unite the leading big pharma, pioneering biotechs, and leading academics to cement preclinical and translational confidence to accelerate therapeutics in the clinic.
Key Highlights for 2023:
Decipher predictive and pharmacodynamic TGF-β biomarkers for patient identification to illuminate the right patient population with BioAtla
Shining a spotlight on the basic science and pathway biology to de-risk and re-stratify drug development programs for future therapeutic success with UCSF
Assessing the clinical journeys to overcome the challenges faced to safely and successfully unlock TGF-β for immuno-oncology with Genentech, Pliant Therapeutics, Scholar Rock, and Duke University
Analyze the opportunity in novel strategies to illuminate new directions to tame the double-edged sword that is the TGF-β pathway with EpicentRx and Morphic Therapeutics
Delve into combinational strategies to balance toxicity and efficacy to supercharge an effective therapeutic through the pipeline with Corbus Pharmaceuticals and The Oregon Clinic
Presenting Companies Include:
